FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2021

ABBVIE INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other Jurisdiction of Incorporation)

001-35565
(Commission File Number)

32-0375147
(IRS Employer Identification No.)

1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, $0.01 Par Value</td>
<td>ABBV</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>1.500% Senior Notes due 2023</td>
<td>ABBV23B</td>
<td>Chicago Stock Exchange</td>
</tr>
<tr>
<td>1.375% Senior Notes due 2024</td>
<td>ABBV24</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>1.250% Senior Notes due 2024</td>
<td>ABBV24B</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>0.750% Senior Notes due 2027</td>
<td>ABBV27</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>2.125% Senior Notes due 2028</td>
<td>ABBV28</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>2.625% Senior Notes due 2028</td>
<td>ABBV28B</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>2.125% Senior Notes due 2029</td>
<td>ABBV29</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>1.250% Senior Notes due 2031</td>
<td>ABBV31</td>
<td>New York Stock Exchange</td>
</tr>
</tbody>
</table>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □
Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 16, 2021, AbbVie Inc. amended and restated the AbbVie Performance Incentive Plan, as amended and restated, the AbbVie Supplemental Executive Retirement Plan, as amended and restated, and the AbbVie Supplemental Savings Plan, as amended and restated (collectively, the “Plans”), to provide eligibility under the Plans and/or Exhibit A to the Plans, as applicable, to AbbVie employees who were participants in the AbbVie Pension Plan as of January 1, 2013 and designated as “officers” under Section 16 of the Securities Exchange Act of 1934 prior to January 1, 2018.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date: December 17, 2021

By: /s/ Timothy J. Richmond

Timothy J. Richmond
Executive Vice President,
Chief Human Resources Officer